81 results
To evaluate the feasibility and prove the concept of sentinel node biopsy in patients with carcinoma of the parotid gland and scheduled for parotidectomy and elective neck dissection.
To evaluate the efficacy and safety of T-817MA in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
To assess safety and efficacy of AMX0035 for treatment of ALS.
To evaluate the efficacy of two doses of norucholic acid vs. placebo for the treatment of primary biliary cholangitis (PBC) in patients with an inadequate response to ursodeoxycholic acid (UDCA).
Part 1: dose optimizationTo identify a clinically active and tolerable systemic exposure range of bezuclastinib in subjects with AdvSMPart 2 Stage 1: Dose ConfirmationTo confirm the optimal dose of bezuclastinib in subjects with AdvSMPart 2 Stage 2…
Primary: • To evaluate whether long-term treatment with bempedoic acid 180 mg/day versus placebo reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease (CVD) who are statin…
Primary• To evaluate the effect of CK-3773274 on exercise capacity (VO2) in patients with symptomatic oHCMSecondary• To evaluate the effect of CK-3773274 on patient health status• To evaluate the effect of CK-3773274 on New York Heart Association (…
DOSE ESCALATION PHASE: PART A: Primary Objectives: • To assess the safety and tolerability of KBA1412 when given as monotherapy. • To determine the maximum tolerated dose (MTD) and/or Recommended Phase II dose (RP2D) of KBA1412 when given as…
The objectives of this study are to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of intra-articular (IA) AMB-05X in the treatment of tenosynovial giant cell tumor (TGCT), both after an initial 24 weeks of treatment (…
The objective of this trial is to collect additional safety data.The further objective of this trial is to collect long-term efficacy measures as well as to assess the treatment effect on:- disability and productivity- functional impairment- health-…
This study is evaluating the preliminary efficacy of UV1-olaparib-durvalumab combination against both olaparib as monotherapy and olaparib-durvalumab combination in maintenance after platinum combination therapy for BRCAwt patients with relapsed…
Primary Objectives* To assess the pharmacodynamic effects of systemic prednisolone on the LPS- or IMQ-induced inflammatory response* To assess safety & tolerability of intradermal LPS and topical IMQ in combination with prednisoloneSecondary…
The primary objective of this study is to assess the diagnostic accuracy, in terms of sensitivity and negative predictive value, of preoperative 68Ga-Tilmanocept PET/CT combined with conventional lymphoscintigraphy for SLN detection. Besides, we aim…
The purposes of this clinical trial are to:• Test if trial participants taking uproleselan with standard chemotherapy medicines live longer than those taking standard chemotherapy alone. • Test if the number of trial participants achieving disease…
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study drug CT1812 in subjects with mild to moderate Alzheimer*s disease. The efficacy of CT1812 will be compared to the efficacy of a placebo. A placebo is a…
Primary ObjectivesParts 1 and 2: To evaluate the safety and tolerability, describe any dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) or highest protocol- defined doses (in the absence of exceeding the MTD) and the…
The primary objective of this trial in CIAS is to assess the efficacy in improving cognitive impairment using MCCB in patients with schizophrenia treated for 26 weeks with Iclepertin 10mg as compared with placebo.
Primary Objective: To evaluate the safety and efficacy of 2 concentrations of Atropine Sulfate OphthalmicSolution (0.01% and 0.02%) compared to Vehicle (placebo) for slowing the progression of myopia inchildren over a 3-year treatment period.…